Cogent Biosciences (COGT) Cash from Financing Activities (2017 - 2026)

Cogent Biosciences (COGT) has 10 years of Cash from Financing Activities data on file, last reported at $52.5 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 110.4% year-over-year to $52.5 million in Q1 2026; TTM through Mar 2026 was $905.8 million, a 3471.2% increase from a year earlier, with the FY2025 full-year figure at $878.2 million, up 309.53% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $52.5 million, down from $588.7 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for COGT reached as high as $588.7 million in Q4 2025 and fell as low as -$256000.0 in Q2 2024.
• Historically, Cash from Financing Activities has averaged $92.0 million across 5 years, with a median of $13.0 million in 2023.
• Across the five-year window, Cash from Financing Activities slumped 100.16% in 2024 and soared 2264011.54% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at $315000.0 in 2022, then surged by 217.46% to $1.0 million in 2023, then slumped by 97.4% to $26000.0 in 2024, then surged by 2264011.54% to $588.7 million in 2025, then slumped by 91.08% to $52.5 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $52.5 million in Q1 2026, $588.7 million in Q4 2025, and $217.4 million in Q3 2025.